In recent years, it has been demonstrated that AHNAK serves as a novel prognostic biomarker in different types of cancer, such as pancreatic ductal adenocarcinoma, triple-negative breast cancer, and BC [48–50]. This evidence concerns the gene AHNAK and triple-negative breast carcinoma.